ArticleCerebral circulation - cognition and behavior2025
FDG-PET anterior cingulate cortex hypometabolism as a marker of cerebral small vessel disease in Alzheimer's and vascular cognitive impairment and dementia.
Article in Cerebral circulation - cognition and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Imaging markers of vascular cognitive impairment: Current advances and future directions.Cerebral circulation - cognition and behavior · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The anterior cingulate cortex (ACC) is an important hub in the executive and salience networks. While fluorodeoxyglucose-positron emission tomography (FDG-PET) is valuable in dementia diagnosis, there is no FDG-PET imaging 'signature' in vascular cognitive impairment and dementia (VCID). We investigated whether ACC hypometabolism on FDG-PET brain imaging in people with VCID correlated with cerebral small vessel disease (CSVD), estimated via white matter hyperintensity (WMH) severity, and clinical features, comparing these results with an Alzheimer dementia (AD) cohort. Methods: We performed a retrospective clinical database review of patients seen at a specialist cognitive neurology service between 2009 and 2024 to identify patients with VCID and AD diagnoses. Demographic details, cognitive (Addenbrooke's Cognitive Examination-Revised, ACE-R) and behavioural (Cambridge Behavioural Inventory, CBI) screens were collated where available. Two clinicians independently performed unblinded, visual assessments of clinical FDG-PET maps, rating for the presence or absence of ACC hypometabolism. WMH severity was estimated via Fazekas scale on clinical MRI as a measure of CSVD. Results: 379 people were identified: 98 VCID (median (IQR) age: 71 (63-77)), and 281 CE (median (IQR) age 72 (66-79)). ACC hypometabolism was observed more frequently in people with VCID (74 %) than AD (34 %). ACC hypometabolism correlated with greater vascular risk factor burden and higher Fazekas scores. Conclusion: ACC hypometabolism correlated with WMH severity but was not specific to VCID. ACC hypometabolism on FDG-PET may represent a functional marker of vascular damage to frontal-subcortical circuits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.